- Assistant Professor, Fred Hutch Human Biology Division
Fred Hutch Cancer Center
1100 Fairview Ave. N.
Mail Stop C1-015
Seattle, WA 98109
Office: Hutchinson Building, C1-019
Lab: Hutchinson Building, C1-187
Select from the following:
Dr. Behnam Nabet is a cancer chemical biologist who develops cutting-edge technologies to target key cancer-causing proteins. Rather than block or disable a protein, Nabet focuses his studies on developing strategies that exploit the cell’s mechanisms for degrading proteins to eliminate cancer-causing proteins with speed and precision. These innovative technologies identify promising drug candidates and deepen our understanding of the molecular circuits that are critical for cancer cell growth and survival. Nabet also works to adapt this approach into therapeutic strategies to deliver new solutions for cancers that resist current therapies.
Research Interests:
The Nabet lab is dedicated to targeting oncogenic signaling networks through control of protein homeostasis to advance new therapeutic strategies in cancer. We use multidisciplinary approaches including development of degradation-based technologies to discover, validate, and gain insights into clinically relevant targets. We believe in collaborative and open-source science and are committed to supporting the next-generation of scientists.
- Postdoctoral Fellowship, Dana-Farber Cancer Institute, Harvard Medical School
- PhD, Northwestern University
- Advance innovative therapeutic modalities and treatment paradigms for patients with difficult-to-treat cancers
Koide E, Mohardt ML, Doctor ZM, Yang A, Hao M, Donovan KA, Kuismi CC, Nelson AJ, Abell K, Aguiar M, Che J, Stokes MP, Zhang T, Aguirre AJ, Fischer ES, Gray NS, Jiang B#, Nabet B#. Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity. ChemBioChem. 2023 Oct 4;24(19):e202300141. (#Co-Corresponding Author)
Kuismi CC, Nabet B. Lighting the way to tumor destruction. Trends in Pharmacological Sciences. 2023 Sep 25:S0165-6147(23)00205-5.
Olson AT, Kang Y, Ladha AM, Zhu S, Lim CB, Nabet B, Lagunoff M, Gujral TS, Geballe AP. Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation. PLoS Pathogens. 2023 Sep 5;19(9):e1011169.
Yao Y, Fong Ng J, Park WD, Samur MK, Morelli E, Encinas J, Chyra Z, Xu Y, Derebail S, Epstein CB, Nabet B, Chesi M, Gray NS, Young R, Kwiatkowski N, Mitsiades CS, Anderson KC, Lin CY, Munshi NC, Fulciniti M. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023 Jun 8;141(23):2841-2852.
Trory JS, Munkacsi A, Śledź KM, Vautrinot J, Goudswaard LJ, Jackson ML, Heesom KJ, Moore SF, Poole AW, Nabet B, Aggarwal VK, Hers I. Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function. Blood Advances. 2023 May 9;7(9):1692-1696.
Lu W, Fan M, Ji W, Tse J, You I, Ficarro SB, Tavares I, Che J, Kim AY, Zhu X, Boghossian A, Rees MG, Ronan MM, Roth JA, Hinshaw SM, Nabet B, Corsello SM, Kwiatkowski N, Marto JA, Zhang T, Gray NS. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors. Journal of Medicinal Chemistry. 2023 Apr 13;66(7):4617-4632.